Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

OBJECTIVE: To examine the impact on quality of life (QOL) of patients with hATTR amyloidosis with polyneuropathy treated with inotersen (Tegsedi™) versus placebo. METHODS: Data were from the NEURO-TTR trial (ClinicalTrials.gov Identifier: NCT01737398), a phase 3, multinational, randomized, double-bl...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Neurol
Main Authors: Coelho, Teresa, Yarlas, Aaron, Waddington-Cruz, Marcia, White, Michelle K., Sikora Kessler, Asia, Lovley, Andrew, Pollock, Michael, Guthrie, Spencer, Ackermann, Elizabeth J., Hughes, Steven G., Karam, Chafic, Khella, Sami, Gertz, Morie, Merlini, Giampaolo, Obici, Laura, Schmidt, Hartmut H., Polydefkis, Michael, Dyck, P. James B., Brannagan III, Thomas H., Conceição, Isabel, Benson, Merrill D., Berk, John L.
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2019
Assuntos:
Original Communication
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109169/
https://ncbi.nlm.nih.gov/pubmed/31853709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-019-09671-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares